Cargando…
Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565178/ http://dx.doi.org/10.1192/j.eurpsy.2022.685 |
_version_ | 1784808824395268096 |
---|---|
author | Romero Guillena, S.L. De Burgos Berdud, I. Gálvez Medina, R. Serrano Rodriguez, E. |
author_facet | Romero Guillena, S.L. De Burgos Berdud, I. Gálvez Medina, R. Serrano Rodriguez, E. |
author_sort | Romero Guillena, S.L. |
collection | PubMed |
description | INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with a dual diagnosis of schizophrenia and substance use disorder Secondary: To compare the rate of fully vaccinated patients diagnosed with schizophrenia with and without a coexisting substance use disorder. METHODS: Retrospective descriptive study. The population in study is made up of patients with schizophrenia (46) and dual diagnosis schizophrenia (28) (following DSM 5 criteria) Confirmed cases were those cases with positive PCR RESULTS: There was not a stadistically significant difference in the prevalence of COVID 19 infection between both groups of patients. The prevalence of COVID infection among the dual diagnosis schizophrenia was 3.57% compared to 6.5% in those without coexisting substance abuse disorder. Relative to vaccination rate, we didn’t find a stadistically significant difference between both groups. However, there was a higher vaccination rate in the dual diagnosis schizophrenia group (82.12%) compared to the non-dual diagnosis schizophrenia group (69.56%) CONCLUSIONS: The prevalence of COVID 19 infection in the dual diagnosis schizophrenia cohort is 3.57% and in the group of patients with schizophrenia without substance abuse disorder is 6,5%. In those with dual diagnosis schizophrenia the vaccination rate was un 82.12%. It was 69.56% in those without coexisting substance abuse disorder. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9565178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95651782022-10-17 Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder Romero Guillena, S.L. De Burgos Berdud, I. Gálvez Medina, R. Serrano Rodriguez, E. Eur Psychiatry Abstract INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with a dual diagnosis of schizophrenia and substance use disorder Secondary: To compare the rate of fully vaccinated patients diagnosed with schizophrenia with and without a coexisting substance use disorder. METHODS: Retrospective descriptive study. The population in study is made up of patients with schizophrenia (46) and dual diagnosis schizophrenia (28) (following DSM 5 criteria) Confirmed cases were those cases with positive PCR RESULTS: There was not a stadistically significant difference in the prevalence of COVID 19 infection between both groups of patients. The prevalence of COVID infection among the dual diagnosis schizophrenia was 3.57% compared to 6.5% in those without coexisting substance abuse disorder. Relative to vaccination rate, we didn’t find a stadistically significant difference between both groups. However, there was a higher vaccination rate in the dual diagnosis schizophrenia group (82.12%) compared to the non-dual diagnosis schizophrenia group (69.56%) CONCLUSIONS: The prevalence of COVID 19 infection in the dual diagnosis schizophrenia cohort is 3.57% and in the group of patients with schizophrenia without substance abuse disorder is 6,5%. In those with dual diagnosis schizophrenia the vaccination rate was un 82.12%. It was 69.56% in those without coexisting substance abuse disorder. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9565178/ http://dx.doi.org/10.1192/j.eurpsy.2022.685 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Romero Guillena, S.L. De Burgos Berdud, I. Gálvez Medina, R. Serrano Rodriguez, E. Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
title | Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
title_full | Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
title_fullStr | Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
title_full_unstemmed | Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
title_short | Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
title_sort | prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565178/ http://dx.doi.org/10.1192/j.eurpsy.2022.685 |
work_keys_str_mv | AT romeroguillenasl prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder AT deburgosberdudi prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder AT galvezmedinar prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder AT serranorodrigueze prevalenceandcovid19vaccinationrateinapopulationofpatientswithschizophreniaandasubstanceusedisorder |